Premium
Prolonged survival of an HIV‐infected patient with plasmablastic lymphoma of the oral cavity
Author(s) -
Panos George,
Karveli Efthymia A.,
Nikolatou Ourania,
Falagas Matthew E.
Publication year - 2007
Publication title -
american journal of hematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.456
H-Index - 105
eISSN - 1096-8652
pISSN - 0361-8609
DOI - 10.1002/ajh.20807
Subject(s) - plasmablastic lymphoma , medicine , vincristine , lymphoma , pancytopenia , cyclophosphamide , prednisolone , lesion , chop , biopsy , chemotherapy , pathology , gastroenterology , bone marrow
Plasmablastic lymphoma is an aggressive subtype of diffuse large B‐cell lymphoma that is mainly observed in patients with the human immunodeficiency virus (HIV) infection, and it tends to arise in the oral cavity. We present a case of an HIV‐infected patient with plasmablastic lymphoma with prolonged survival. The 30‐yr‐old woman was found to have an oral lesion at the time of the diagnosis of HIV infection. Histological and immunochemical examination of biopsy of the oral lesion showed plasmablastic lymphoma (CD138+). She received two cycles of cyclophosphamide, vincristine, doxorubicin, and prednisolone (CHOP) that started 10 weeks after the initiation of antiretroviral therapy. The continuing pancytopenia and an adenoviral febrile infection did not permit further antineoplastic treatment. A gradual decrease of the oral lesion was noted after the second cycle of chemotherapy that led to the disappearance of the lesion 7 months later. The patient remains in complete remission 61 months after the diagnosis of plasmablastic lymphoma. Am. J. Hematol., 2007. © 2006 Wiley‐Liss, Inc.